What is the official website of Cipla Therapeutics ?

The official website of Cipla Therapeutics is https://http://www.cipla.com.

What is Cipla Therapeutics's cybersecurity risk score?

Cipla Therapeutics has an AI-generated cybersecurity risk score of 757 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Cipla Therapeutics experienced?

According to Rankiteo, Cipla Therapeutics currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Cipla Therapeutics been affected by any supply chain cyber incidents ?

According to Rankiteo, Cipla Therapeutics has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Cipla Therapeutics have SOC 2 Type 1 certification ?

According to Rankiteo, Cipla Therapeutics is not certified under SOC 2 Type 1.

Does Cipla Therapeutics have SOC 2 Type 2 certification ?

According to Rankiteo, Cipla Therapeutics does not hold a SOC 2 Type 2 certification.

Does Cipla Therapeutics comply with GDPR ?

According to Rankiteo, Cipla Therapeutics is not listed as GDPR compliant.

Does Cipla Therapeutics have PCI DSS certification ?

According to Rankiteo, Cipla Therapeutics does not currently maintain PCI DSS compliance.

Does Cipla Therapeutics comply with HIPAA ?

According to Rankiteo, Cipla Therapeutics is not compliant with HIPAA regulations.

Does Cipla Therapeutics have ISO 27001 certification ?

According to Rankiteo,Cipla Therapeutics is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Cipla Therapeutics operate in ?

Cipla Therapeutics operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Cipla Therapeutics have ?

Cipla Therapeutics employs approximately None employees people worldwide.

Does Cipla Therapeutics own any subsidiaries ?

Cipla Therapeutics presently has no subsidiaries across any sectors.

How many LinkedIn followers does Cipla Therapeutics have ?

Cipla Therapeutics's official LinkedIn profile has approximately 12,320 followers.

What is the NAICS classification code for Cipla Therapeutics ?

Cipla Therapeutics is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Cipla Therapeutics have a Crunchbase profile ?

No, Cipla Therapeutics does not have a profile on Crunchbase.

Does Cipla Therapeutics have a LinkedIn profile ?

Yes, Cipla Therapeutics maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/cipla-therapeutics.

How many cybersecurity incidents has Cipla Therapeutics experienced ?

As of June 9, 2026, Rankiteo reports that Cipla Therapeutics has not experienced any cybersecurity incidents.

How many peer or competitor companies does Cipla Therapeutics have ?

Cipla Therapeutics has an estimated 5,682 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Cipla Therapeutics

Boost Score +25 with badge (5 left)

757

/1000

Fair

782

/1000

Fair

Cipla Therapeutics Vendor Cyber Rating & Cyber Score

cipla.com

Add Your Compliance Badge

Cipla Therapeutics is the branded, specialty institutional business division of Cipla USA, Inc.

Cipla Therapeutics A.I CyberSecurity Scoring

Scoring History

Cipla Therapeutics

Cipla Therapeutics CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Cipla Therapeutics Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Cipla Therapeutics

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Cipla Therapeutics in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Cipla Therapeutics in 2026.

Incident Types Cipla Therapeutics vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Cipla Therapeutics in 2026.

Incident History - Cipla Therapeutics (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Cipla Therapeutics Subsidiaries

Cipla Therapeutics

Pharmaceutical Manufacturing

Website: https://http://www.cipla.com

Company Size: None employees

CiplaPharmaceutical Manufacturing

Cipla AfricaPharmaceutical Manufacturing

The CEO Lens PodcastPharmaceutical Manufacturing

Cipla FoundationNon-profit Organizations

Cipla Australia & New ZealandPharmaceutical Manufacturing

Cipla ALIVEPharmaceutical Manufacturing

Loading…

Cipla Therapeutics Similar Companies

Bristol Myers Squibb

cb bms.com

At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html

Viatris

viatris.com

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.

Eli Lilly and Company

lilly.com

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.

Teva Pharmaceuticals

tevapharm.com

Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Zydus Group

zyduslife.com

The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life-sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 27000 people worldwide and is driven by its mission to unlock new possibilities in life-sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through pathbreaking discoveries.

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Loading…

NEWS

Cipla Therapeutics CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

July 29, 2008 07:00 AM

Cipla Medpro Pharmaceuticals, South Africa

Cipla Medpro Pharmaceuticals is listed on the Johannesburg Securities Exchange and is one of South Africa's top ten and fastest-growing pharmaceutical groups.

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-44541

SUMMARY

Fides is an open-source privacy engineering platform. From version 2.33.0 to before version 2.84.5, there is a DOM-based XSS vulnerability in fides.js via the fides_description override. This issue has been patched in version 2.84.5.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: )

cvss4

Base Score: 7.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:N/VA:N/SC:H/SI:H/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-49141

SUMMARY

WACRM prior to commit 73041bf contain an authorization bypass vulnerability in the automation engine that allows authenticated attackers to access and modify contacts belonging to other tenants by supplying an arbitrary caller-controlled contact_id in the POST request body without tenant ownership verification. Attackers can exploit the service-role client that bypasses row-level security to modify victim contact fields including name, email, and company across tenant boundaries using only a known contact UUID.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: 7.1)

cvss3

Base Score: 7.1

Complexity: HIGH

CVSS:3.1/AV:N/AC:H/PR:L/UI:N/S:C/C:L/I:H/A:N

cvss4

Base Score: 5.1

Complexity: HIGH

CVSS:4.0/AV:N/AC:H/AT:N/PR:L/UI:N/VC:N/VI:N/VA:N/SC:L/SI:H/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

4.7

Exploitability

1.8

REFERENCES

CVE-2026-47345

SUMMARY

Namespace attributes are not encoded correctly during HTML serialization. This allows bypassing the cross-site scripting prevention mechanism of typo3/html-sanitizer before version 2.3.2.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: )

cvss4

Base Score: 5.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:N/VI:N/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-47344

SUMMARY

When ALLOW_INSECURE_RAW_TEXT is enabled, whitespace-variant closing tags (e.g., </style\t>) are not recognized by the sanitizer but accepted by browsers as valid end tags, allowing subsequent content to escape sanitization. This allows bypassing the cross-site scripting prevention mechanism of typo3/html-sanitizer before version 2.3.2.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: )

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:P/PR:L/UI:P/VC:N/VI:N/VA:N/SC:L/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

Exploitability

REFERENCES

CVE-2026-46484

SUMMARY

Headplane is a feature-complete Web UI for Headscale. Prior to versions 0.6.3 and 0.7.0-beta.3, Headplane was vulnerable to a path traversal / authorization bypass in the Headscale API client used by node and user rename operations. This issue has been patched in versions 0.6.3 and 0.7.0-beta.3.

Published

Date2026-06-08

Updated

Date2026-06-08

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…